Back to catalogue
№ 097 14 filings · 2021-12-31 → 2026-08-04

GEORGIA CAPITAL PLC

CGEO
Financial Services Share price 4,400p Market cap £1.3bn Overall fit 235 /1000

Well-run Georgian holdco with strong balance sheet and NAV track record, but essentially zero AI-receiver exposure, only moderate operating leverage, and the historical NAV discount has narrowed from ~40% to ~10% — the cheap-holdco thesis is largely spent, leaving limited margin of safety for this investor's strategy.

Fair value range 4,260p–4,760p Mid case · £1.4bn
Absolute upside +3.6% vs current market cap
Conviction 4/5 confidence in fair call
Supports the call
  • Lion Finance stake is a liquid listed asset with transparent market value
  • Independent Kroll valuations of private portfolio, semi-annual, validated by recent exits at/above carrying value
  • Fortress HoldCo balance sheet (net cash, NCC -2.9%, S&P BB Stable)
Limits the call
  • 47% of NAV is a single bank stock — near-term returns driven by Lion Finance share price
  • Georgian political/EU-accession risk is hard to price and could rapidly re-widen the NAV discount
Methodology

Sum-of-parts NAV with holding-company discount

In one line · bull case

Well-run Georgian investment holding company with a fortress balance sheet, strong NAV track record and aggressive capital returns — but the previously deep NAV discount has largely closed.

In one line · biggest risk

47% of NAV is Lion Finance shares plus Georgian country/geopolitical risk, meaning any shock could simultaneously widen the discount and mark down the portfolio.

Drivers
AI beneficiary 8 /100
Zero direct AI exposure — Georgian bank, pharmacy, hospitals, insurance, hydropower, private schools; no picks-and-shovels or AI-augmented revenue lines anywhere in the portfolio.
Operating leverage 45 /100
Moderate — 1H26 large-portfolio revenue +16.4% y-o-y translated to EBITDA +23.9% (~1.5x leverage); pharmacy margin only 11.7%, hospitals 21.1%; no software-style leverage.
Earnings vs expectations 65 /100
Management beat its own targets consistently (capital return programme completed a year early, NCC target of 10% achieved at -2.9%), though no conventional analyst consensus to measure against.
Growth momentum 75 /100
Strong — eight consecutive quarters of double-digit revenue growth at large private portfolio; Georgian GDP +7.9% 1H26; NAV/share +33.7% CAGR over 3 years.
Moat 55 /100
Mixed — Lion Finance is a top-2 Georgian bank with real deposit franchise; pharmacy is #1 with 33.7% share; hospitals leading; but all in a small national market with limited defensibility beyond local scale.
Earnings quality 70 /100
Good — Kroll independently values private assets semi-annually; recent exits (m2, beer, water utility) validated NAV; dividend inflows growing.
Management quality 75 /100
Strong track record on capital allocation — completed full investment cycle on water utility (2.9x MOIC), disposed of beer and housing at premium prices, aggressive buybacks (35% of peak share count).
Cyclicality 55 /100
Moderate — banking, insurance, healthcare, retail pharmacy have differing sensitivities; overall exposure to Georgian macro and Lion Finance share price adds cyclical/beta exposure.
Leverage 15 /100
Extremely low — HoldCo is in net cash post local bond redemption (settling Aug 2026); NCC ratio -2.9% is a record low.

Georgia Capital PLC (CGEO) — Investment Research Note

Executive Summary

Georgia Capital is a London-listed investment holding company that owns a portfolio of Georgian businesses — a 14.9% stake in Lion Finance Group (formerly Bank of Georgia), plus wholly/majority-owned private companies in pharmacy retail, hospitals, insurance, renewable energy and education. NAV per share has compounded at a remarkable ~34% CAGR in GEL over the last three years, driven by Lion Finance's share price rally and strong operating results across a resilient Georgian macro backdrop. The single most important valuation point today is that the historically wide discount to NAV has almost fully closed (shares at 4,485p vs. 30 June 2026 NAV of ~5,010p, or a ~10% discount versus ~40-50% historically), meaning the "cheap holdco" thesis that drove the last two years of returns is largely spent.

Fair value estimate

Methodology: Sum-of-parts / NAV with a holding-company discount. GCAP publishes a fully-marked NAV (Lion Finance at market; private companies valued by Kroll semi-annually using DCF cross-checked with peer multiples; Emerging/Other on DCF or EV/EBITDA). The 30 June 2026 NAV was GEL 175.12/share ≈ 5,010p per share (GBP 50.10). 2026-08 half-year report

Assumptions:

  • Apply a 5–15% discount to reported NAV — narrower than the 30-40% historical average, but justified by (a) demonstrated exit execution (m2 housing sale June 2026, beer sale 2024, water utility 2022/25), (b) HoldCo net cash position, (c) S&P BB rating aligned with sovereign, (d) active buyback + capital return programme (GEL 1bn through 2029, at least half via buybacks/dividends).
  • Additional deduction not applied for Lion Finance PFIC dilution risk (already reduced to 14.9%).

Fair value range: 4,260p – 4,760p per share (implied market cap £1,310m – £1,465m).

  • Midpoint: ~4,510p / £1,388m
  • Current market cap: £1,381.6m
  • Absolute upside/downside: ~+0.6% (essentially fair value)

The current price effectively marks the stock at NAV less a modest 10% discount — leaving little margin of safety unless one underwrites continued 15–20% annual NAV compounding, which requires Lion Finance to keep re-rating.

Sector context

Confirmed sector: Financial Services (Financials) — as a diversified investment holding company. In practice CGEO is closer to a listed private-equity / country fund. There are no true UK-listed peers; comparables would be closed-end country funds (frontier markets), Turkey's Sabanci Holding, or Kazakhstan's Kaspi (very different mix). Compared to typical Financials peers, CGEO has: (a) above-average growth (Georgia GDP +7.9% 1H26); (b) higher country/geopolitical risk; (c) unusual "look-through" cash conversion since the Bank is 90%+ of listed-market value inside CGEO.

Investment thesis (3 bullets)

  • Fortress balance sheet + aggressive capital return. HoldCo is now in net cash (NCC ratio -2.9%, a record low), S&P upgraded to BB (Stable) in June 2026, and management has launched a GEL 1bn capital allocation programme through 2029, with at least half committed to buybacks/dividends. 35% of peak issued share capital has been bought back since demerger. 2026-08 half-year report
  • Underlying operating momentum is strong. Aggregate revenue at large private portfolio companies +19.1% y-o-y in 2Q26 (eighth consecutive quarter of double-digit growth); EBITDA +21.2%. Georgia's macro (nominal GDP +11.8% y-o-y 2Q26, IMF raised 2026 growth forecast to 6.5%) provides a supportive tailwind. 2026-08 half-year report
  • Demonstrated exit track record. m2 housing sold (June 2026), beer/distribution 80% sold to Royal Swinkels (2024), water utility fully exited (2021-2025 put/call cycle at 2.9x MOIC). Management is willing to monetise mature assets at strategic-buyer premiums, which supports NAV credibility. 2026-06 disposal; 2024-10 beer disposal; 2025-08 half-year report

Key risks (3 bullets)

  • Georgian country/political risk. EU accession suspended until at least 2028; US "MEGOBARI Act" sanctions and visa restrictions on Georgian officials; ruling party's "foreign influence" law strained Western relations; founder of Georgian Dream personally sanctioned by US in Dec 2024. Region-specific risks (Russia/Ukraine, Israel/Iran) also loom. Any escalation would immediately hit both Lion Finance's share price and private-asset multiples. 2026-08 half-year report — Principal Risks
  • Concentration in Lion Finance (46.9% of portfolio). GCAP's NAV is highly geared to a single Georgian bank stock. Lion Finance shares are up 22% q-o-q in 2Q26 and 97.5% in FY25 — much of the recent NAV growth is a directional bet on one asset. Any bank-specific setback (asset quality, regulatory, currency) or reversal of the rating would hit NAV hard. 2026-08 half-year report
  • Discount-narrowing thesis is spent. The gap between share price and NAV was the main return driver 2023-2026. Now at ~10%, further contraction is limited; total returns from here depend on NAV growth alone, and the 34% NAV CAGR of the last three years is unlikely to be sustainable at that rate. Board explicitly notes the discount has "significantly narrowed." 2026-08 half-year report

Operating leverage

Operating leverage in the underlying portfolio is moderate, not high. Aggregated 1H26 large-portfolio revenues +16.4% y-o-y translated to EBITDA +23.9% — implies ~1.5x operating leverage, which is consistent but not exceptional. By segment: retail (pharmacy) EBITDA margin is only 11.7% (2Q26) so incremental revenue drops through at a modest rate; healthcare services runs a 21.1% EBITDA margin with meaningful fixed costs at hospitals (occupancy at 76.8% for large/specialty in 2Q26, +6.3ppt y-o-y — showing volume-driven margin expansion); insurance has ~90% combined ratio with moderate scale economics; emerging businesses (renewables, education) are more capital-intensive with higher fixed-cost bases. A 10-20% aggregate revenue beat would plausibly translate to ~15-30% incremental EBITDA growth — real but not multiplicative. There is no software-style operating leverage anywhere in the portfolio. 2026-08 half-year report; 2026-02 final results

Value-trap signals

None identified — the opposite, in fact. NAV/share has compounded strongly, the balance sheet is deleveraging, capital returns are accelerating, S&P rated up, dividends from portfolio companies are rising, and disclosure quality is high (independent Kroll valuations semi-annually). If anything, the risk is that the stock is now correctly priced for a good story, not that it is cheap for a bad reason.

Earnings vs. expectations

CGEO is a NAV story, not a consensus-EPS story — sell-side coverage is thin and management doesn't issue quarterly guidance in the conventional sense. Where management has set concrete targets, they have been beaten: (a) GEL 700m capital return programme completed "well over a year ahead" of the original December 2027 timeline; (b) NCC ratio target was 10%, actual is -2.9%; (c) large portfolio revenue growth has now delivered eight consecutive quarters of double-digit growth. On the "hitting internal targets" measure, the pattern is consistent delivery, but this is a "not enough conventional consensus data" situation rather than a real analyst beat track record.

Conviction

Conviction: 4 (high).

Anchors: (a) NAV is very well disclosed — Lion Finance is a listed liquid asset; Kroll independently values the large private assets semi-annually; management provides detailed segment financials. (b) Track record of monetising private assets at premium to carrying value (water utility, beer, m2) validates NAV credibility. (c) Balance sheet is unambiguously strong (net cash HoldCo).

Caveats: (i) Georgian country risk is real and hard to price — a discount narrowing or widening driven by geopolitics is not something a bottom-up model can predict; (ii) 47% of NAV is a single bank stock whose share price movement dominates near-term returns.

Overall assessment for this investor's strategy

CGEO is a well-run, well-disclosed Georgian holding company with a genuine track record. It is not, however, a fit for this investor's specific mandate. There is zero AI-receiver exposure — the portfolio is retail pharmacy, hospitals, insurance and a Georgian bank. Operating leverage is moderate at best. Valuation has run from a deep NAV discount to near-parity, meaning the entry price now requires believing continued NAV compounding rather than mean reversion of a discount. Downside protection is genuinely good (net cash HoldCo, diversified assets, defensible businesses), but that alone is not enough to overcome the strategy-mismatch. This is a "know about, don't chase" name for this portfolio.

Filings consulted · 25

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-08-04Half Year Financial Report2026-08-04_9702442_half-year-financial-report.md0.90
  2. 2026-06-09Result OF Agm2026-06-09_9609446_result-of-agm.md0.30
  3. 2026-06-05Disposal OF The Housing Development Business2026-06-05_9604940_disposal-of-the-housing-development-business.md0.75
  4. 2026-05-11Notice OF Agm2026-05-11_9562449_notice-of-agm.md0.30
  5. 2026-02-24Final Results2026-02-24_9443335_final-results.md1.00
  6. 2025-08-06Half Year Report2025-08-06_9030421_half-year-report.md0.58
  7. 2025-05-20Result OF Agm2025-05-20_8888020_result-of-agm.md0.20
  8. 2025-04-11Notice OF Agm2025-04-11_8825918_notice-of-agm.md0.20
  9. 2025-02-24Final Results2025-02-24_8748417_final-results.md0.65
  10. 2024-12-23Completion OF Disposal OF Beer And Distribution2024-12-23_8628688_completion-of-disposal-of-beer-and-distribution.md0.49
  11. 2024-10-28Disposal OF The Beer And Distribution Business2024-10-28_8511735_disposal-of-the-beer-and-distribution-business.md0.49
  12. 2024-08-13Half Year Report2024-08-13_8362886_half-year-report.md0.41
  13. 2024-05-20Result OF Agm2024-05-20_8208923_result-of-agm.md0.14
  14. 2024-04-12Notice OF Agm2024-04-12_8134270_notice-of-agm.md0.14
  15. 2024-02-22Final Results2024-02-22_8050031_final-results.md0.45
  16. 2023-08-15Half Year Report2023-08-15_7695759_half-year-report.md0.23
  17. 2023-05-17Result OF Agm2023-05-17_7531436_result-of-agm.md0.07
  18. 2023-04-13Notice OF Agm2023-04-13_7488431_notice-of-agm.md0.07
  19. 2023-02-20Final Results2023-02-20_7485829_final-results.md0.25
  20. 2022-10-04Completion OF Disposal OF Water Utility Business2022-10-04_7201483_completion-of-disposal-of-water-utility-business.md0.19
  21. 2022-05-20Result OF Agm2022-05-20_6972572_result-of-agm.md0.07
  22. 2022-04-12Notice OF Agm2022-04-12_6941923_notice-of-agm.md0.07
  23. 2022-02-23Final Results2022-02-23_6924261_final-results.md0.25
  24. 2022-02-03Disposal2022-02-03_6707824_disposal.md0.19
  25. 2021-12-31Disposal2021-12-31_6725568_disposal.md0.19

This research note was authored by a large language model after reading 14 regulatory filings published between 2021-12-31 and 2026-08-04. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.